<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":7977,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Celsis In Vitro, Inc. v. CellzDirect, Inc., 664 F.3d 922, 101 U.S.P.Q.2d 1153 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/35c10b58c7ceea3c31799530ef1ba5ee'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/35c10b58c7ceea3c31799530ef1ba5ee'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1GUIDM003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1GUIDM003">Previous Result: <span>Felicien v. PNC Mortgage &amp; Wells Fargo, ...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1GUIGI003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1GUIGI003">Next Result: <span>United States v. Edwards, No. CASE NO: 8...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Celsis In Vitro, Inc. v. CellzDirect, Inc., 664 F.3d 922, 101 U.S.P.Q.2d 1153 (Fed. Cir. 2012), Court Opinion'>
Celsis In Vitro, Inc. v. CellzDirect, Inc., 664 F.3d 922, 101 U.S.P.Q.2d 1153 (Fed. Cir. 2012),...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Celsis In Vitro, Inc. v. CellzDirect, Inc., 664 F.3d 922, 101 U.S.P.Q.2d 1153 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1GU4Q2003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Celsis In Vitro, Inc. v. CellzDirect, Inc.</div>
<div class='displayCitation'>101 U.S.P.Q.2d 1153</div>
<div class='displayCitation'>2012 BL 3552</div>
<div class='displayCitation'>664 F.3d 922</div>
<div class='displayCitation'>bna a0d0g3f8q7</div>
<div class='displayCitation'>bna a0d0g3p1m4</div>
<div class='displayCitation'>wkffecase:25659809</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1GU4Q2003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Celsis In Vitro, Inc. v. CellzDirect, Inc., 664 F.3d 922, 101 U.S.P.Q.2d 1153 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Celsis In Vitro, Inc. v. CellzDirect, Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1GU4Q2003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1GU4Q2003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1GU4Q2003" /><input id="title" name="title" type="hidden" value="Celsis In Vitro, Inc. v. CellzDirect, Inc., 664 F.3d 922, 101 U.S.P.Q.2d 1153 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="35c10b58c7ceea3c31799530ef1ba5ee" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1GU4Q2003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%33%35c%31%30b%35%38c%37ceea%33c%33%31%37%39%39%35%33%30ef%31ba%35ee%2Fdocument%2FX%31GU%34Q%32%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/bcite/X1GU4Q2003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/bcite/X1GU4Q2003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/bcite/X1GU4Q2003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/related_content/X1GU4Q2003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1681641242627";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">664 F.3d 922</div>
<div class="cite" data-cite-type="ReporterOfDecisions">101 U.S.P.Q.2d 1153</div>
<div class="cite" data-cite-type="DocketNumber">2010-1547</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 3552</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
CELSIS IN VITRO, INC., Plaintiff-Appellee, v. CELLZDIRECT, INC., and
Invitrogen Corporation, Defendants-Appellants.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 2010-1547.
</center></p>
<p><center>
January 9, 2012.
<span CLASS="page_no" data-cite="101 uspq 2d 1154" data-cite-type="ReporterOfDecisions" data-cite-pageno="1154" data-primary-citation="101 U.S.P.Q.2d 1153">[**1154]</span> </center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_441980" href="#headnote_ref_pq2-dec_441980">[1]</a> <span>Patent construction &mdash; Claims &mdash; Broad or narrow </span> <a href="http://www.bloomberglaw.com/document/1681641242627/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=125.1303" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="125.1303">&#9658;125.1303</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnote_text">
Claim directed to method of preparing multi-cryopreserved hepatocyte cells, which recites cryopreservation of viable hepatocytes to form desired preparation &ldquo;without requiring a density gradient step,&rdquo;
simply means that claim does not require step of subjecting hepatocytes to density gradient fractionation, not that density gradient step is prohibited, and performance of step by accused method therefore does not preclude finding of infringement.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_441981" href="#headnote_ref_pq2-dec_441981">[2]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1681641242627/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Long felt need </span> <a href="http://www.bloomberglaw.com/document/1681641242627/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0909" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0909">&#9658;115.0909</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnote_text">
Infringement plaintiff is likely to succeed in demonstrating that invention of patent claiming methods for preparing multi-cryopreserved hepatocyte cells is not invalid for obviousness, since invention is in unpredictable art, and despite fact that art was crowded field for many years, there was no reference to multi-cryopreservation, since single round of freezing severely damages hepatocytes and results in lower cell viability, and plaintiff has shown that, at time of invention, person of ordinary skill in art would expect second freezing on those damaged cells to kill even more cells than first freezing, since prior art reference cited by defendants does not describe or suggest more than one round of freezing, or &ldquo;pooling&rdquo;
of multi-cryopreserved hepatocyte cells, since defendants' reference to &ldquo;market need&rdquo; is actually probative of long-felt need under objective criteria analysis, and thus is supportive of nonobviousness, and since none of defendants' experts testified to actually performing claimed process or documenting their understanding of it before time of invention, despite having financial, scientific, and professional incentive to do so.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">REMEDIES</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_441982" href="#headnote_ref_pq2-dec_441982">[3]</a> <span>Non-monetary and injunctive &mdash; Equitable relief &mdash;
Preliminary injunctions &mdash; Patents </span> <a href="http://www.bloomberglaw.com/document/1681641242627/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=505.0707.07" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="505.0707.07">&#9658;505.0707.07</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnote_text">
Finding that infringement plaintiff would suffer irreparable harm absent preliminary injunction is affirmed, since price erosion, loss of goodwill, damage to reputation, and loss of business opportunities found by federal district court are all valid grounds for irreparable harm, and mere possibility of future monetary damages does not defeat motion for preliminary injunction, and since plaintiff offered unrebutted expert testimony, as well as fact testimony and specific financial records, on issue of irreparable harm, including expert testimony on damage to plaintiff's product price, reputation, and business opportunities;
defendants' argument that effects of defendants' conduct can be quantifiable because parties are in two-competitor market was not raised before district court, and will not be considered on appeal.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_441983" href="#headnote_ref_pq2-dec_441983">[4]</a> <span>Non-monetary and injunctive &mdash; Equitable relief &mdash;
Preliminary injunctions &mdash; Bond </span> <a href="http://www.bloomberglaw.com/document/1681641242627/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=505.0707.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="505.0707.03">&#9658;505.0707.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Non-monetary and injunctive &mdash; Equitable relief &mdash;
Preliminary injunctions &mdash; Patents </span> <a href="http://www.bloomberglaw.com/document/1681641242627/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=505.0707.07" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="505.0707.07">&#9658;505.0707.07</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_6" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_6" class="headnoteContent"></div>
<div class="headnote_text">
Finding that balance of harms favors issuance of preliminary injunction is affirmed, since, absent injunction, infringement plaintiff would lose value of its patent and suffer irreparable harms demonstrated through unrebutted expert testimony, since loss of goodwill and reputation that defendants claim they will suffer upon issuance of preliminary injunction would also be incurred by plaintiff in absence of injunction, since federal district court properly considered defendants' interest in fulfilling current contract obligations, and did not clearly err in rejecting defendants' claims that injunction would force them to shut down operations, and since record suggests that defendants took calculated risk of selling accused product with knowledge of plaintiff's patent; district court did not abuse its discretion in setting amount of bond, despite defendants' argument that bond is inadequate, since defendants did not accept district court's invitation to present additional evidence to substantiate higher bond.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_441984" href="#headnote_ref_pq2-dec_441984">[5]</a> <span>Non-monetary and injunctive &mdash; Equitable relief &mdash; Preliminary injunctions &mdash; Patents </span> <a href="http://www.bloomberglaw.com/document/1681641242627/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=505.0707.07" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="505.0707.07">&#9658;505.0707.07</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_7" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_7" class="headnoteContent"></div>
<div class="headnote_text">
Public interest supports issuance of injunction in action for infringement of patent claiming methods for preparing multi-cryopreserved hepatocyte cells, since investment in drug research and development must be encouraged and protected by exclusionary rights conveyed in valid patents, and since that incentive would be adversely affected by taking market benefits from patentee and giving them to accused infringer; although defendants argue that they sell products for drug research and development, and that public interest thus would disfavor enjoining them, parties are direct competitors, and public can obtain products at issue from plaintiff.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
  Appeal from the United States District Court for the
Northern District of Illinois, Milton I. Shadur, J.
</p></div>
<span CLASS="page_no" data-cite="664 f 3d 923" data-cite-type="PrimaryFederalReporter" data-cite-pageno="923" data-primary-citation="664 F.3d 922">[*923]</span> <div id="contentOpinion" printdualcolumn="true"><div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="664 f 3d 924" data-cite-type="PrimaryFederalReporter" data-cite-pageno="924" data-primary-citation="664 F.3d 922">[*924]</span> 
</p></div></div>
<div id="para2" printdualcolumn="true"><p>
  Adam G. Kelly, Loeb &amp; Loeb, LLP, of Chicago, IL, argued
for plaintiff-appellee. With him on the brief was Jordan A.
Sigale. Of counsel was Julie L. Langdon.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Francis M. Wikstrom, Parsons Behle &amp; Latimer, of Salt Lake
City, UT, argued for defendants-appellants. With him on the
brief were David G. Mangum, C. Kevin Speirs and Michael R.
McCarthy.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before RADER, Chief Judge, GAJARSA, and PROST, Circuit
Judges.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Opinion for the court filed by Chief Judge RADER. Dissenting
opinion filed by Circuit Judge GAJARSA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  RADER, Chief Judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The United States District Court for the Northern District
of Illinois granted Celsis In Vitro, Inc's ("Celsis") motion
for a preliminary injunction against CellzDirect, Inc. and
Invitrogen Corporation, now Life Technologies Corporation
("LTC"). Based on the record, the district court did not abuse
its discretion. This court affirms.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>I.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Celsis is the assignee of U.S. Patent No. <cite>7,604,929</cite> (filed Apr.
21, 2005) ("the &prime;<cite>929</cite> patent"), which claims methods for
preparing multi-cryopreserved hepatocytes (a type of liver
cell). Claims 1 and 10 of the &prime;<cite>929</cite> patent are on appeal:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  1. A method of producing a desired preparation of
  multi-cryopreserved hepatocytes, said hepatocytes,
  being capable of being frozen and thawed at least two
  times, and in which greater than 70% of the
  hepatocytes of said preparation are viable after the
  final thaw, said method comprising:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (A) subjecting hepatocytes that have been frozen and
  thawed to <i>density gradient fractionation</i> to
  separate viable hepatocytes from non-viable
  hepatocytes,
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (B) recovering the separated viable hepatocytes, and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (C) cryopreserving the recovered viable hepatocytes to
  thereby form said desired preparation of hepatocytes
  <i>without requiring a density gradient step</i>
  after thawing the hepatocytes for the second time,
  wherein the hepatocytes are not plated between the
  first and second cryopreservations, and wherein
  greater than 70% of the hepatocytes of said
  preparation are viable after the final thaw.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  10. A method of investigating in vitro drug metabolism
  comprising incubating hepatocytes of a
  multi-cryopreserved hepatocyte preparation in the
  presence of a xenobiotic, and determining the
  metabolic fate of the xenobiotic, or the affect of the
  xenobiotic on the hepatocytes or on an enzyme or
  metabolic activity thereof, wherein the hepatocytes
  have been frozen and thawed at least two times, and
  wherein greater than 70% of the hepatocytes of said
  preparation are viable <i>without requiring a density</i>
  <i>gradient step</i> after thawing the hepatocytes for
  the second time, <span CLASS="page_no" data-cite="101 uspq 2d 1155" data-cite-type="ReporterOfDecisions" data-cite-pageno="1155" data-primary-citation="101 U.S.P.Q.2d 1153">[**1155]</span> wherein the hepatocytes are not
  plated between the first and second <span CLASS="page_no" data-cite="2012 bl 3552 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> cryopreservations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
&prime;<cite>929</cite> patent col. 19 1. 56 &mdash; col. 20 1. 19, 11.
49-59 (emphasis added to the disputed claim terms).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The specification of the &prime;<cite>929</cite> patent explains that human
hepatocytes are a useful
<span CLASS="page_no" data-cite="664 f 3d 925" data-cite-type="PrimaryFederalReporter" data-cite-pageno="925" data-primary-citation="664 F.3d 922">[*925]</span> 
laboratory model for evaluating drug candidates. Two
problems, however, have limited their use. First, hepatocytes
have a short lifespan which causes an inconsistent and limited
supply. Specifically, the only sources of fresh hepatocytes are
liver resections or non-transplantable livers of multi-organ
donors. Due to this reliance on liver donation, fresh
hepatocytes become available at unpredictable times.
Researchers must wait until a liver donation and must often
resume or begin research with little advance warning. This
unpredictability hinders laboratory studies, which usually
require a consistent source of supplies. This supply problem
also limits research geographically to the region near the
liver donor.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To obtain a more consistent supply, scientists sought
techniques for long-term storage of hepatocytes in the
laboratory. The option of cryopreservation (freezing) did not
work well because freezing extensively damages hepatocyte
cells. Hepatocytes are extremely fragile and, once damaged, do
not recover. Thus, even a single instance of cryopreservation
can jeopardize the need for a sufficient level of viable
hepatocytes. For this reason, experts in this field met initial
attempts to freeze hepatocytes with skepticism.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The second problem is outlier data. If a researcher uses
hepatocytes from only one or two donors, the results may not be
representative of the larger population. To avoid this, the
researcher needs a pool of hepatocytes from a larger group of
different liver donors to minimize the effect of outliers. Once
again, the unpredictability of liver donations jeopardizes the
effort to accumulate a representative pool of hepatocytes. Of
course, multiple liver donations are unlikely to occur at the
same time. Therefore, the researcher must rely on preserving
hepatocytes to accumulate a pool. Specifically, the researcher
must combine frozen hepatocytes with fresh hepatocytes to
create a pool. Because the pool must be used immediately, any
unused cells are discarded; otherwise, refreezing would freeze
the thawed cells a second time. Thus, preservation methods
severely limit, or even preclude, pooled hepatocyte products.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;<cite>929</cite> patent intends to solve these problems while
retaining substantial hepatocyte cell viability through a
method of multi-cryopreserving hepatocyte cells. Celsis
developed its LiverPool&trade; pooled multi-cryopreserved
hepatocyte products, which it asserts are covered by the
&prime;<cite>929</cite> patent. LTC also sells pooled multi-cryopreserved
hepatocyte products, which Celsis alleges involve performing a
process infringing the &prime;<cite>929</cite> patent ("the accused
process"). For confidentiality reasons, this decision does not
give the details of the accused process.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In June 2010, Celsis sued LTC for infringement of the
&prime;<cite>929</cite> patent. Celsis moved for a preliminary injunction.
After <span CLASS="page_no" data-cite="2012 bl 3552 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> a month of discovery, the district court conducted a
five-day evidentiary hearing. The district court, upon
consideration of the testimony and written submissions, ruled
from the bench and granted Celsis a preliminary injunction. LTC
moved for a stay pending appeal, which the district court
denied.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  LTC appealed the district court's grant of a preliminary
injunction. It moved for a stay pending appeal, which this
court denied in <i>Celsis In Vitro, Inc. v. CellzDirect,</i>
<i>Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1EMKSO003?jcsearch=404%20f%20appx%20481&amp;summary=yes#jcite">404 Fed.Appx. 481</a> (Fed. Cir. 2010). This court has
jurisdiction under <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XEIMUA003?jcsearch=28%20U.S.C.%20%201292(c)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1292</a>(c)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>II.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court reviews a district court's decision to grant a
motion for preliminary injunction for an abuse of discretion.
<span CLASS="page_no" data-cite="664 f 3d 926" data-cite-type="PrimaryFederalReporter" data-cite-pageno="926" data-primary-citation="664 F.3d 922">[*926]</span> 
<i>Abbott Labs. v. Sandoz, Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X19R7I0003?jcsearch=544%20f%203d%201341&amp;summary=yes#jcite">544 F.3d 1341</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X19R7I0003?jcsearch=544%20f%203d%201341&amp;summary=yes#jcite">1345</a>
(Fed. Cir. 2008). To constitute an abuse of discretion, a
district court decision must either make a clear error of
judgment in weighing relevant factors or exercise discretion
based upon an error of law. <i><a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X19R7I0003?jcsearch=544%20F.3d%201341&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court analyzes four factors when considering a
preliminary injunction: (1) likelihood of success on the
merits, (2) irreparable harm, (3) balance of hardships, and (4)
public interest. <i></i><a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X19R7I0003?jcsearch=544%20F.3d%201341&amp;summary=yes#jcite">Id. at 1344</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                  <b>III.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found that Celsis had shown a likelihood of
success on the merits. The district court also considered LTC's
defenses: non-infringement, obviousness, written description,
and inequitable conduct. LTC has chosen to appeal only the
first two.
<span CLASS="page_no" data-cite="101 uspq 2d 1156" data-cite-type="ReporterOfDecisions" data-cite-pageno="1156" data-primary-citation="101 U.S.P.Q.2d 1153">[**1156]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As to infringement, the district court weighed the testimony of
Celsis' expert Dr. Steven C. Strom against the testimony of
LTC's marketing director Markus J. Hunkeler. The district court
found Dr. Strom's testimony to be helpful in carefully
explaining how LTC's accused process meets all the limitations
of the asserted claims. In contrast, the district court found
that Mr. Hunkeler "really didn't offer anything in the way of
opinions to address the proper interpretation of the patent's
claims." Preliminary Injunction Hr'g Tr. 4:10-12, Sept. 7,
2010.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Thus, the district court found that Celsis is likely to succeed
in proving that LTC's accused process performs all the steps in
the asserted claims. First, Dr. Strom gave testimony on the
proper reading of the term "density gradient fractionation" in
step (A) of claim 1. Then, he applied that term to the accused
process. He testified that the accused process performs a
density separation that satisfies the "density gradient
fractionation" in step (A), because it separates viable from
nonviable hepatocytes by density. Though Mr. Hunkeler testified
that the accused process performs an "isodensity" separation
that does not create a gradient, the district court found
Celsis' expert Dr. Strom's testimony more persuasive.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, with that claim construction in place, LTC asserted an
alternative non-infringement defense based on step (C). LTC
presented documents showing that the accused process performs
the same density separation after the first thaw (step A) and
the second thaw (step C) only in a different medium. In
contrast to step (A), step (C) includes the language
"<i>without requiring</i> a density gradient step."
&prime;<cite>929</cite> patent col. 20 l. 15, ll. 57-58 (emphasis added).
LTC reads "without requiring" <span CLASS="page_no" data-cite="2012 bl 3552 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> to mean "prohibiting," such that
the accused process performs an action "prohibited" by step (C)
and therefore does not infringe. LTC made the same argument
about claim 10.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found this argument to be "hokum" and an
improper attempt to insert a limitation not in the claims. Hr'g
Tr. 5:13. In finding for Celsis, the district court adopted Dr.
Strom's expert testimony by reference to Celsis' post-hearing
briefing. The district court concluded: "In sum, it is an
understatement to say that Celsis has shown substantially more
than a reasonable likelihood of success on the subject of
infringement." Hr'g Tr. 7:3-5.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_441980" href="#headnote_pq2-dec_441980">[1]</a> This record shows that the district court did not abuse its
discretion in finding a likelihood of success on infringement.
LTC errs in reading "without requiring" to mean "prohibiting."
The claim language is not susceptible to this unnatural
reading. Instead, "without requiring" means simply that the
claim does not require the density
<span CLASS="page_no" data-cite="664 f 3d 927" data-cite-type="PrimaryFederalReporter" data-cite-pageno="927" data-primary-citation="664 F.3d 922">[*927]</span> 
gradient step. Thus, performance of that step does not
preclude a finding of infringement. For that reason, this court
need not reach LTC's subsequent argument concerning performance
of the "density gradient step" in step (C). This court also
declines to reach the joint infringement issue that LTC raised
for the first time at oral argument. <i>See Henry v. DOJ</i>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X36HSD?jcsearch=157%20f%203d%20863&amp;summary=yes#jcite">157 F.3d 863</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X36HSD?jcsearch=157%20f%203d%20863&amp;summary=yes#jcite">865</a> (Fed. Cir. 1998) (not considering an argument
raised for the first time at oral argument); <i>Darwin Constr.</i>
<i>Co. v. United States</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X4AEBJ?jcsearch=811%20f%202d%20593&amp;summary=yes#jcite">811 F.2d 593</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X4AEBJ?jcsearch=811%20f%202d%20593&amp;summary=yes#jcite">596</a> n. 1
(Fed. Cir. 1987) (same).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As to non-obviousness, the district court reviewed the
testimony and submissions of Celsis and LTC's fact and expert
witnesses. It noted the "vast proliferation of authors and
articles dealing with hepatocytes and use of cryopreservation."
Hr'g Tr. 7:15-17. But, the district court found: "[N]ot a
single one of that astonishingly large body of literature was
devoted to the subject of <i>multi</i>-cryopreservation of
hepatocytes." Hr'g Tr. 7:19-22 ("I have properly laid stress on
`multi.'").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court rejected LTC's attempt to fill that gap.
LTC's expert Dr. Sanjeev Gupta opined that the only reference
to multi-cryopreservation in the prior art is an article in
2002 that he co-authored ("the Malhi article"). <i>See</i>
Harmeet Malhi et al., <i>Isolation of human progenitor liver</i>
<i>epithelial cells with extensive replication capacity and</i>
<i>differentiation into mature hepatocytes</i>, 115 (13) Journal
of Cell Science 2679 (2002). The Malhi article discusses fetal
hepatocytes as experiment models because they can replicate in
laboratory conditions (unlike mature or adult hepatocytes). The
essence of the article was not to introduce a new method or
advance in cryopreservation but instead to focus on the
advantages of using fetal hepatocytes due to their replication
abilities. The Malhi article does report on the "poor viability
of hepatocytes after cryopreservation."
<span CLASS="page_no" data-cite="101 uspq 2d 1157" data-cite-type="ReporterOfDecisions" data-cite-pageno="1157" data-primary-citation="101 U.S.P.Q.2d 1153">[**1157]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found Dr. Gupta's testimony unpersuasive
and, as to the Malhi article, found that "nothing in that
skeletal reference suggests or even hints at the advance
conceived of by the inventor here." Hr'g Tr. 8:14-15. The
district court instead credited Celsis' expert <span CLASS="page_no" data-cite="2012 bl 3552 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> Dr. Strom who
testified that due to the independent replication of the fetal
hepatocytes, it could not be definitively determined whether
the same cells were cryopreserved more than once. Dr. Gupta
also conceded this same point. The district court found that
LTC was attempting to make much of "a wisp of a term that is
buried in the Malhi article." Hr'g Tr. 8:2-3. It deemed LTC's
arguments to be nothing more than "second guessing and
hindsight." Hr'g Tr. 8:17-18. The district court concluded that
"again Celsis has demonstrated more than a substantial
likelihood of success on the issue." Hr'g Tr. 10:8-9.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The issue on appeal is whether the district court erred in
finding Celsis likely to succeed on non-obviousness in view of
G. de Sousa et al., <i>Increase of cytochrome P-450 1A and</i>
<i>glutathione transferase transcripts in cultured hepatocytes</i>
<i>from dogs, monkeys, and humans after cryo-preservation</i>, 12
Cell Biology and Toxicology 351 (1996) ("the de Sousa
article"). On appeal, LTC does not assert its obviousness
argument based on the Malhi article, despite LTC's own expert
Dr. Gupta opining that Malhi was the only reference in the
prior art that allegedly disclosed multi-cryopreservation.
Instead of disclosing multi-cryopreservation, the de Sousa
article analyzes whether single-cryopreserved hepatocytes can
replace fresh hepatocytes as laboratory models, by comparing
fresh versus (single) cryopreserved human, monkey, and dog
hepatocytes. Specifically,
<span CLASS="page_no" data-cite="664 f 3d 928" data-cite-type="PrimaryFederalReporter" data-cite-pageno="928" data-primary-citation="664 F.3d 922">[*928]</span> 
while previous studies determined the effect of single
cryopreservation on fresh hepatocytes by evaluating differences
in cell viability, cell attachment, and protein synthesis, the
aim of this article was to evaluate whether three different
chemicals could induce (<i>i.e.</i> increase activity of) two
different enzymes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>, a patent claim is invalid "if the
differences between the subject matter sought to be patented
and the prior art are such that the subject matter as a whole
would have been obvious at the time the invention was made to a
person having ordinary skill in the art." The obviousness
analysis is based on underlying factual inquiries including:
(1) the scope and content of the prior art; (2) the level of
ordinary skill in the art; (3) the differences between the
claimed invention and the prior art; and (4) objective evidence
of nonobviousness. <i>Eli Lilly &amp; Co. v. Teva Pharm. USA</i>
<i>Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1E54SG003?jcsearch=619%20f%203d%201329&amp;summary=yes#jcite">619 F.3d 1329</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1E54SG003?jcsearch=619%20f%203d%201329&amp;summary=yes#jcite">1336</a> (Fed. Cir. 2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This preliminary record shows that the district court did not
abuse its discretion in finding that Celsis has shown a
likelihood of success on nonobviousness. LTC will have an
opportunity at the merits stage to expand upon the arguments it
made at the preliminary injunction stage. The record as it now
stands, however, reveals no clear error by the district court.
And this court does not opine on the final determination, which
lays in the realm of the district court in the first instance.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_441981" href="#headnote_pq2-dec_441981">[2]</a> As an initial matter, this court acknowledges that the present
invention is in an art well-known for its unpredictability. As
to the scope and content of the prior art, the district court
correctly emphasized and found <span CLASS="page_no" data-cite="2012 bl 3552 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> based on the preliminary record
that the art was a crowded field for many years and yet there
was not one reference to multi-cryopreservation. Moreover, the
record shows that the prior art taught away from multiple
freezings. A single round of freezing severely damages
hepatocyte cells and results in lower cell viability. Celsis
provided a sufficient showing at this preliminary injunction
stage that, at the time of the invention, a person of ordinary
skill would expect a second freezing on those damaged cells to
kill even more cells than the first freezing. Celsis provides a
helpful analogy. Imagine a runner who finishes one marathon and
then immediately begins a second marathon. One would not expect
the runner to perform the second in the same time as the first.
More likely, the runner would not even finish the second
marathon. Similarly, as Celsis' expert Dr. Strom testified, one
would expect lower cell viability and a greater loss of cells
after the second cryopreservation than after the first, thus
teaching away from multi-cryopreservation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With respect to the de Sousa article, this court sees no error
in the district court's reliance on Dr. Strom's testimony that
de Sousa does not describe or suggest more than one round of
freezing, nor does it describe or suggest pooling. Instead, de
Sousa only discloses a single cryopreservation. Even LTC's
expert <span CLASS="page_no" data-cite="101 uspq 2d 1158" data-cite-type="ReporterOfDecisions" data-cite-pageno="1158" data-primary-citation="101 U.S.P.Q.2d 1153">[**1158]</span> Dr. Gupta did not testify that de Sousa discloses
multi-cryopreservation. This court has not seen LTC identify
any teaching, suggestion, or motivation in the de Sousa
article that multiple rounds of freezing would somehow increase rather
than decrease cell viability. Instead, to make this leap, LTC
makes vague references to "market need" and testimony from its
witnesses Dr. Gupta and Dr. Albert Li. Without more, this
reference to "market need," properly linked to the claimed
invention, is actually probative of long felt need under
objective criteria analysis and supportive of non-obviousness.
<span CLASS="page_no" data-cite="664 f 3d 929" data-cite-type="PrimaryFederalReporter" data-cite-pageno="929" data-primary-citation="664 F.3d 922">[*929]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Gupta opined on a "more resistance" theory, and Dr. Li
opined on a "mathematical calculation" theory. Specifically,
Dr. Gupta (opining specifically on the de Sousa article)
claimed that cells that survived the first freeze would be
"more resistant" and therefore more likely to survive a second
freeze. Dr. Li (opining generally, not specifically on the de
Sousa article) claimed that the same number of cells that
survived the first freeze would survive the second freeze. The
de Sousa article does not disclose either of these hindsight
theories.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court did not find the testimony of LTC's experts
Dr. Gupta and Dr. Li credible. The district court has wide
discretion to weigh expert credibility. <i>Conoco, Inc. v.</i>
<i>Energy &amp; Envtl. Int'l, L.C.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X15HQJ4003?jcsearch=460%20f%203d%201349&amp;summary=yes#jcite">460 F.3d 1349</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X15HQJ4003?jcsearch=460%20f%203d%201349&amp;summary=yes#jcite">1362-63</a>
(Fed. Cir. 2006) ("As for the relative weight given to the
testimony of both sides' expert witnesses, we accord the trial
court broad discretion in determining credibility because the
court saw the witnesses and heard their testimony.") (quoting
<i>Energy Capital Corp. v. United States</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XE7CER?jcsearch=302%20f%203d%201314&amp;summary=yes#jcite">302 F.3d 1314</a>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XE7CER?jcsearch=302%20f%203d%201314&amp;summary=yes#jcite">1329</a> (Fed. Cir. 2002)); <i>Bristol-Myers Squibb Co. v.</i>
<i>Rhone-Poulenc Rorer, Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X6CH0P?jcsearch=326%20f%203d%201226&amp;summary=yes#jcite">326 F.3d 1226</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X6CH0P?jcsearch=326%20f%203d%201226&amp;summary=yes#jcite">1236</a>
(Fed. Cir. 2003) ("<span CLASS="page_no" data-cite="2012 bl 3552 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> Moreover, the district court did not find
convincing or credible the opinion of RPR's expert. . . . [T]he
district court is best suited to make credibility
determinations, and we accord such determinations deference.")
(citing <i>Refac Int'l Ltd. v. Lotus Dev. Corp.</i>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X3A14A?jcsearch=81%20f%203d%201576&amp;summary=yes#jcite">81 F.3d 1576</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X3A14A?jcsearch=81%20f%203d%201576&amp;summary=yes#jcite">1582</a> (Fed. Cir. 1996)). This court defers to such
credibility determinations. <i>Nilssen v. Osram Sylvania,</i>
<i>Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X17PG5U003?jcsearch=504%20f%203d%201223&amp;summary=yes#jcite">504 F.3d 1223</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X17PG5U003?jcsearch=504%20f%203d%201223&amp;summary=yes#jcite">1231-32</a> (Fed. Cir. 2007) ("While an
opposite conclusion could have been reached, it is not the
function of a court of appeals to override district court
judgments on close issues, where credibility findings have been
made."); <i>Agfa Corp. v. Creo Prods. Inc.</i>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X159CD8003?jcsearch=451%20f%203d%201366&amp;summary=yes#jcite">451 F.3d 1366</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X159CD8003?jcsearch=451%20f%203d%201366&amp;summary=yes#jcite">1379</a> (Fed. Cir. 2006) ("This court must defer heavily to
the trial court's credibility determinations. . . . Credibility
determinations by the trial judge can virtually never be clear
error.") (quoting <i>JVW Enters., Inc. v. Interact</i>
<i>Accessories, Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X13A2S0003?jcsearch=424%20f%203d%201324&amp;summary=yes#jcite">424 F.3d 1324</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X13A2S0003?jcsearch=424%20f%203d%201324&amp;summary=yes#jcite">1334</a> (Fed. Cir. 2005)).
Thus, these determinations of credibility also buttress the
record for nonobviousness.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Here, the district court found that the LTC expert's
"revisionist history is unpersuasive." Hr'g Tr. 10:7-8; <i>see</i>
<i>also</i> Hr'g Tr. 7:11-13 ("Instead of a more candid `Why
didn't I think of that,' we get [LTC arguing] `Anybody
reasonably skilled in the art would have thought of that.'").
Not one of LTC's experts testified to actually performing the
claimed process or documenting their alleged understanding
before the time of the invention, despite having the financial,
scientific, and professional incentive to do so. The district
court found that LTC's experts did not predict the results of
the claimed methods at the time of the invention, nor could
they find any reference in the prior art suggesting that any
other scientist had. Hr'g Tr. 7:23-8:1 ("That was not the
subject of numerous articles authored or assembled by Dr. Li or
Dr. Gupta or by any of the other scientists who participated,
in the consortium about which Dr. Li testified, or for that
matter by anybody else."). Accordingly, in this preliminary
injunction context, this court determines that the district
court did not clearly err in finding a person of ordinary skill
in the art likely would not have found the invention obvious
either.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In sum, the record supports the district court's conclusion
that Celsis has shown a likelihood of success that a person of
ordinary skill in the art would not have considered the claimed
methods obvious at the time of the invention.
<span CLASS="page_no" data-cite="664 f 3d 930" data-cite-type="PrimaryFederalReporter" data-cite-pageno="930" data-primary-citation="664 F.3d 922">[*930]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>IV.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found that Celsis would suffer irreparable
harm absent a preliminary injunction. As the district court
recognized, the simple fact that one could, if pressed, compute
a money damages award does not always preclude a finding of
irreparable harm. As its name implies, the irreparable harm
inquiry seeks to measure harms that no damages payment, however
great, could address. <i>See <span CLASS="page_no" data-cite="101 uspq 2d 1159" data-cite-type="ReporterOfDecisions" data-cite-pageno="1159" data-primary-citation="101 U.S.P.Q.2d 1153">[**1159]</span> Altana Pharma AG v. Teva Pharm.</i>
<i>USA Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1B3L62003?jcsearch=566%20f%203d%20999&amp;summary=yes#jcite">566 F.3d 999</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1B3L62003?jcsearch=566%20f%203d%20999&amp;summary=yes#jcite">1010</a> (Fed. Cir. 2009); <i>see also</i>
<i>Sampson v. Murray</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C8Q3?jcsearch=415%20us%2061&amp;summary=yes#jcite">415 U.S. 61</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C8Q3?jcsearch=415%20us%2061&amp;summary=yes#jcite">90</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C8Q3?jcsearch=94%20supreme%20court%20937&amp;summary=yes#jcite">94 S.Ct. 937</a>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C8Q3?jcsearch=39%20l%20ed%202d%20166&amp;summary=yes#jcite">39 L.Ed.2d 166</a> (1974) ("The key word in this consideration is
<i>irreparable.</i> Mere injuries, however substantial, in
terms of money, time and energy necessarily expended in the
absence of a stay, are not enough.") (quoting <i>Va. Petroleum</i>
<i>Jobbers Ass'n v. Fed. Power Comm'n</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X41LJN?jcsearch=259%20f%202d%20921&amp;summary=yes#jcite">259 F.2d 921</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X41LJN?jcsearch=259%20f%202d%20921&amp;summary=yes#jcite">925</a>
(D.C. Cir. 1958)). The district court <span CLASS="page_no" data-cite="2012 bl 3552 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> found that the permanent,
irreparable harm to Celsis would include price erosion, damage
to ongoing customer relationships, loss of customer goodwill
(<i>e.g.</i>, when an effort is later made to restore the
original price), and loss of business opportunities. As the
district court explained: "There is no effective way to measure
the loss of sales or potential growth &mdash; to ascertain the
people who do not knock on the door or to identify the specific
persons who do not reorder because of the existence of the
infringer." Hr'g Tr. 16:25-17:4.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_441982" href="#headnote_pq2-dec_441982">[3]</a> Based on the record before the district court, this court sees
no error in the district court's finding that Celsis would
suffer irreparable harm absent a preliminary injunction. Price
erosion, loss of goodwill, damage to reputation, and loss of
business opportunities are all valid grounds for finding
irreparable harm. <i>Abbott Labs. v. Sandoz, Inc.</i>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X19R7I0003?jcsearch=544%20f%203d%201341&amp;summary=yes#jcite">544 F.3d 1341</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X19R7I0003?jcsearch=544%20f%203d%201341&amp;summary=yes#jcite">1362</a> (Fed. Cir. 2008); <i>Sanofi-Synthelabo v.</i>
<i>Apotex, Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X162FRI003?jcsearch=470%20f%203d%201368&amp;summary=yes#jcite">470 F.3d 1368</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X162FRI003?jcsearch=470%20f%203d%201368&amp;summary=yes#jcite">1382-83</a> (Fed. Cir. 2006).
Thus, contrary to LTC's assertions, the district court did not
err as a matter of law in relying on such evidence. Further,
the mere possibility of future monetary damages does not defeat
a motion for preliminary injunction. <i>See Abbott Labs.</i>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X19R7I0003?jcsearch=544%20f%203d%201341&amp;summary=yes#jcite">544 F.3d at 1361-62</a>; <i>Sanofi-Synthelabo</i>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X162FRI003?jcsearch=470%20f%203d%201368&amp;summary=yes#jcite">470 F.3d at 1382</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Celsis offered testimony from its expert Mark Peterson on
irreparable harm. In contrast, LTC did not offer expert
testimony in rebuttal. This court sees no error in the district
court's reliance on Celsis' unrebutted expert testimony. To
substantiate its claims, Celsis presented fact and expert
testimony as well as specific financial records. Celsis
presented evidence of LTC's significantly discounted prices as
well as specific instances when customers purchased from LTC
instead of Celsis. The record also shows that Celsis had a
general no-discount policy to maintain its premium product
pricing that it was forced to break in order to compete with
LTC. The record included evidence that the LiverPool&trade;
products are Celsis' flagship products and that the products
are in their growth phase and will soon be entering the mature
phase with the highest revenues and strongest market position.
The record also included testimony that this market was
particularly sensitive because customers buy in bulk and at
irregular times, such that the loss of a single sale in this
market may be more harmful than for products purchased daily.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Then, Celsis proffered expert testimony on the damage to
Celsis' price, reputation, and business opportunities. Mr.
Peterson testified to the irreversible price erosion. He also
testified to the difficulty in quantifying the effect on
reputation and business due to Celsis being precluded from
marketing to potential and existing customers that it is the
exclusive market leader.
<span CLASS="page_no" data-cite="664 f 3d 931" data-cite-type="PrimaryFederalReporter" data-cite-pageno="931" data-primary-citation="664 F.3d 922">[*931]</span> 
During the growth stage of a product, it is particularly
crucial to be able to distinguish oneself from competitors.
This includes building the brand, expanding the customer base,
and establishing one's reputation and leadership in the market.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court declines to reach LTC's new argument that these
effects can be quantifiable in <span CLASS="page_no" data-cite="2012 bl 3552 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> this case because this is
supposedly a two-competitor market and such harms are allegedly
not irreparable in such a market. LTC chose not to properly
raise this before the district court. The general rule is that
this court does not consider arguments not raised below.
<i>See Singleton v. Wulff</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C97G?jcsearch=428%20us%20106&amp;summary=yes#jcite">428 U.S. 106</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C97G?jcsearch=428%20us%20106&amp;summary=yes#jcite">120</a>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C97G?jcsearch=96%20supreme%20court%202868&amp;summary=yes#jcite">96 S.Ct. 2868</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C97G?jcsearch=49%20l%20ed%202d%20826&amp;summary=yes#jcite">49 L.Ed.2d 826</a> (1976). This court finds no reason to
disregard that rule here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In light of the unrebutted expert testimony, this court finds
no reason to reverse the district court's weighing of evidence
and fact finding that Celsis would suffer irreparable harm
absent a preliminary injunction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>V.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court concluded that "plainly the balancing of
harms tilts heavily in Celsis's favor." Hr'g Tr. 17:11-12. This
preliminary injunction factor is also affected by LTC's
decision not to present expert testimony to rebut Celsis'
expert testimony. The district court found that any asserted
harm to LTC was "of lesser scope" than the harm to Celsis and
also "protectable by a bond." Hr'g Tr. 17:9-11 (citing <i>PPG</i>
<i>Indus., Inc. v. Guardian Indus. Corp.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X573B2?jcsearch=75%20f%203d%201558&amp;summary=yes#jcite">75 F.3d 1558</a>
(Fed. Cir. 1996)).
<span CLASS="page_no" data-cite="101 uspq 2d 1160" data-cite-type="ReporterOfDecisions" data-cite-pageno="1160" data-primary-citation="101 U.S.P.Q.2d 1153">[**1160]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_441983" href="#headnote_pq2-dec_441983">[4]</a> The district court did not clearly err in finding the balancing
of harms favors Celsis. Absent a preliminary injunction, Celsis
would lose the value of its patent as well as suffer the
irreparable harms opined on by its expert. The losses alleged
by LTC <i>upon</i> a preliminary injunction (loss of goodwill
and reputation) would also be incurred by Celsis
<i>absent</i> a preliminary injunction. Moreover, the record
shows that the district court properly considered LTC's
interest in fulfilling its current contract obligations.
<i>See PPG Indus., Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X573B2?jcsearch=75%20f%203d%201558&amp;summary=yes#jcite">75 F.3d at 1567</a>. In fact, the
district court allowed LTC to complete some sales. This court
sees no clear error in the district court rejecting the LTC
witness Mr. Hunkeler's claims that it would have to shut down
operations upon a preliminary injunction. Further, the
preliminary record suggests that LTC's losses were the result
of its own calculated risk in selling a product with knowledge
of Celsis' patent. <i>See Sanofi-Synthelabo v. Apotex,</i>
<i>Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X162FRI003?jcsearch=470%20f%203d%201368&amp;summary=yes#jcite">470 F.3d 1368</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X162FRI003?jcsearch=470%20f%203d%201368&amp;summary=yes#jcite">1383</a> (Fed. Cir. 2006).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As to the bond, this court sees no abuse of discretion in the
district court's bond amount. <i>See Sanofi-Synthelabo</i>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X162FRI003?jcsearch=470%20F.3d%201368&amp;summary=yes#jcite">470 F.3d at 1386</a> ("The amount of a bond is a determination that
rests within the sound discretion of a trial court."). LTC
argues that the bond is inadequate. But, the district court
invited LTC to present additional evidence to substantiate a
higher bond. LTC presented no such evidence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>VI.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_441984" href="#headnote_pq2-dec_441984">[5]</a> The district court found that Celsis had carried its burden to
prove that the public interest would favor a preliminary
injunction. This court sees no error in the district court's
conclusion. The public interest favors the enforcement of
Celsis' patent rights here. <i>See Sanofi-Synthelabo v.</i>
<i>Apotex, Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X162FRI003?jcsearch=470%20f%203d%201368&amp;summary=yes#jcite">470 F.3d 1368</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X162FRI003?jcsearch=470%20f%203d%201368&amp;summary=yes#jcite">1383</a> (Fed. Cir. 2006) ("We
have long acknowledged the importance of the patent system in
encouraging innovation."). Such investment in drug research and
development must be encouraged and protected by the
exclusionary rights conveyed in valid patents. <i>See Abbott</i>
<i>Labs. v. Sandoz, Inc.</i>,
<span CLASS="page_no" data-cite="664 f 3d 932" data-cite-type="PrimaryFederalReporter" data-cite-pageno="932" data-primary-citation="664 F.3d 922">[*932]</span> 
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X19R7I0003?jcsearch=544%20f%203d%201341&amp;summary=yes#jcite">544 F.3d 1341</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X19R7I0003?jcsearch=544%20f%203d%201341&amp;summary=yes#jcite">1362-63</a> (Fed. Cir. 2008). That incentive would
be adversely affected by taking market benefits away from the
<span CLASS="page_no" data-cite="2012 bl 3552 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> patentee and giving them to the accused infringer in this case.
<i>See <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X19R7I0003?jcsearch=544%20F.3d%201341&amp;summary=yes#jcite">id</a>.</i> Though LTC argues that it sells products for
drug research and development such that the public interest
would disfavor enjoining LTC, both LTC and Celsis sell the same
products and are in direct competition. In other words, the
public can obtain the products from Celsis. The record shows
that the district court has considered and properly addressed
the public's interest in obtaining an adequate supply of pooled
multi-cryopreserved hepatocyte products. <i>See PPG Indus.,</i>
<i>Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X573B2?jcsearch=75%20f%203d%201558&amp;summary=yes#jcite">75 F.3d at 1567</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                  <b>VII.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found that all four preliminary injunction
factors favor Celsis. This court sees no reversible error in
the district court's findings. Based on this record, the
district court did not abuse its discretion in granting the
motion for preliminary injunction. This court therefore
affirms.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                  <b>VIII.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court declines to review LTC's new argument that the scope
of the preliminary injunction is overbroad, in terms of
geography and time. <i>See Singleton v. Wulff</i>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C97G?jcsearch=428%20us%20106&amp;summary=yes#jcite">428 U.S. 106</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C97G?jcsearch=428%20us%20106&amp;summary=yes#jcite">120</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C97G?jcsearch=96%20supreme%20court%202868&amp;summary=yes#jcite">96 S.Ct. 2868</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C97G?jcsearch=49%20l%20ed%202d%20826&amp;summary=yes#jcite">49 L.Ed.2d 826</a> (1976). LTC did not
raise this objection before the district court. Nor did it
offer alternative forms to the injunction before the district
court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  GAJARSA, Circuit Judge, dissenting.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I respectfully dissent from the majority's decision to
uphold the "extraordinary and drastic remedy" of a preliminary
injunction because, in my judgment, CellzDirect, Inc. and
Invitrogen Corporation (collectively, "LTC") raised a
substantial question as to the validity of U.S. Patent
No. <cite>7,604,929</cite> (the "&prime;<cite>929</cite> patent"). The grant or denial of a
preliminary injunction is within the broad discretion of the
district court. In this case, however, the district court
committed legal error in granting the preliminary injunction.
The district court's obviousness analysis was legally
deficient, and it erroneously held LTC to a clear and
convincing standard of proof regarding the &prime;<cite>929</cite> patent's
invalidity. By affirming the injunction, the majority
perpetuates these errors and reinvigorates the pre-<i>KSR</i>
standard for obviousness, rigidly requiring an explicit
teaching, suggestion, or motivation for multi-cryopreserving
hepatocytes. <i>Majority Op.</i> at 928.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>I.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Claim 1 of the &prime;<cite>929</cite> patent reads as follows:
<span CLASS="page_no" data-cite="101 uspq 2d 1161" data-cite-type="ReporterOfDecisions" data-cite-pageno="1161" data-primary-citation="101 U.S.P.Q.2d 1153">[**1161]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A method of producing a desired preparation of
  multi-cryopreserved hepatocytes, said hepatocytes,
  being capable of being frozen and thawed at least two
  times, and in which greater than 70% of the
  hepatocytes of said preparation are viable after the
  final thaw, said method comprising: (A) subjecting
  hepatocytes that have been frozen and thawed to
  density gradient fractionation to separate viable
  hepatocytes from non-viable hepatocytes, (B)
  recovering the separated viable hepatocytes, and (C)
  cryopreserving the recovered viable hepatocytes to
  thereby form said desired preparation of hepatocytes
  without requiring a density gradient step after
  thawing the hepatocytes for the second time, wherein
  the hepatocytes are not plated between the first and
  second cryopreservations, and wherein greater than 70%
  of the
<span CLASS="page_no" data-cite="664 f 3d 933" data-cite-type="PrimaryFederalReporter" data-cite-pageno="933" data-primary-citation="664 F.3d 922">[*933]</span> 
  hepatocytes <span CLASS="page_no" data-cite="2012 bl 3552 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> of said preparation are viable after the final thaw.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
&prime;<cite>929</cite> patent col. 19 1. 56-col. 20 1. 20. The district
court held that LTC had not proven that its obviousness defense
had substantial merit because two limitations of the claimed
invention were not present in the prior art: freezing and
thawing hepatocytes a second time and making the density
gradient fractionation optional after the second thaw.
<i>Celsis In Vitro, Inc. v. Cellzdirect, Inc.</i>, Case
No. <cite>10-cv-4053</cite>, Dkt. No. 94 (Sept. 7, 2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Yet obviousness does not require that each element of the
claimed invention must be present in the prior art. Indeed, the
Patent Act precludes such a requirement by stating that
obviousness depends on whether the "<i>differences between the</i>
<i>subject matter sought to be patented and the prior art</i> are
such that the subject matter as a whole would have been obvious
at the time the invention was made to a person having ordinary
skill in the art. . . ." <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103(a)&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>(a) (2006)
(emphasis added). Furthermore, this court has recognized that
proof of obviousness does not require that every element be
present in the prior art. <i>See Tegal Corp. v. Tokyo Electron</i>
<i>Am., Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X510HO?jcsearch=257%20f%203d%201331&amp;summary=yes#jcite">257 F.3d 1331</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X510HO?jcsearch=257%20f%203d%201331&amp;summary=yes#jcite">1349</a> (Fed. Cir. 2001)
(acknowledging that the claimed invention could be obvious even
if prior art did not teach one of its elements).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Moreover, all of the claimed elements were present in the prior
art. Properly interpreted, the claimed invention requires three
steps: (1) thawing cryopreserved hepatocytes; (2) using density
gradient fractionation to separate viable and non-viable cells;
and (3) refreezing and rethawing the hepatocytes. Both
cryopreservation and density gradient fractionation were well
known in the art at the time of the invention. <i>See</i>
&prime;<cite>929</cite> patent col. 2 11. 41-54 (listing prior art
references relating to cryopreservation); J.A. 2981
(Celsis Invitro, Inc.'s ("Celsis") expert Dr. Strom testified that use
of density gradient fractionation to "enhance viability" of
cells is "well-established to everyone in th[e] field."). The
last "step" of the claimed invention requires nothing more than
measuring the viability of cells thawed for a second time. If
the cells have more than 70% viability, they meet this
limitation; if they do not have 70% viability, they do not meet
this limitation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In other words, Celsis' invention uses two known techniques,
repeats them, and happens to obtain 70 percent viability of
hepatocytes. This "invention" is a "patent for a combination
which only unites old elements with no change in their
respective functions [and] obviously withdraws what already is
known into the field of its monopoly," <i>Great Atl.</i>
<i>&amp; Pac. Tea Co. v. Supermarket Equip. Corp.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C1RO?jcsearch=340%20us%20147&amp;summary=yes#jcite">340 U.S. 147</a>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C1RO?jcsearch=340%20us%20147&amp;summary=yes#jcite">152-153</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C1RO?jcsearch=71%20supreme%20court%20127&amp;summary=yes#jcite">71 S.Ct. 127</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X5C1RO?jcsearch=95%20l%20ed%20162&amp;summary=yes#jcite">95 L.Ed. 162</a> (1950), which is a
"principal reason" for finding a patent obvious. <i>KSR Int'l.</i>
<i>Co. v. Teleflex Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. 398</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">416</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XRIK7VQNB5G0?jcsearch=167%20l%20ed%202d%20705&amp;summary=yes#jcite">167 L.Ed.2d 705</a> (2007). Repeating known steps to obtain a
desired result is not inventive. <i>Perfect Web Techs., Inc.</i>
<i>v. InfoUSA Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1C6N6E003?jcsearch=587%20f%203d%201324&amp;summary=yes#jcite">587 F.3d 1324</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1C6N6E003?jcsearch=587%20f%203d%201324&amp;summary=yes#jcite">1330-31</a> (Fed. Cir. 2009)
(finding obvious a claimed invention that required performance
of three steps known in the prior art, followed by repetition
of those steps until a desired result was obtained).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority attempts to complicate the simplicity of the
claimed invention by asserting that the art was <span CLASS="page_no" data-cite="2012 bl 3552 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> unpredictable
while simultaneously asserting that a person of ordinary skill
in the art would have predicted low viability of hepatocytes
that had been frozen and thawed twice. <i>See Majority</i>
<i>Op.</i> at 928. The majority cannot have it both ways. To the
extent the art was unpredictable &mdash; an issue on which the
district court was silent &mdash; this alone does not require a
holding that the invention is
<span CLASS="page_no" data-cite="664 f 3d 934" data-cite-type="PrimaryFederalReporter" data-cite-pageno="934" data-primary-citation="664 F.3d 922">[*934]</span> 
not obvious. <i>See Pfizer, Inc. v. Apotex, Inc.</i>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">480 F.3d 1348</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">1364</a> (Fed. Cir. 2007) ("[O]bviousness cannot be
avoided simply by a showing of some degree of unpredictability
in the art so long as there was a reasonable probability of
success.").
<span CLASS="page_no" data-cite="101 uspq 2d 1162" data-cite-type="ReporterOfDecisions" data-cite-pageno="1162" data-primary-citation="101 U.S.P.Q.2d 1153">[**1162]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority also faults LTC for failing to point out an
explicit teaching, suggestion, or motivation to
multi-cryopreserve hepatocytes.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> <i>Majority Op.</i>
at 928. This is directly contrary to the Supreme Court's opinion
in <i>KSR</i>, which the majority fails to recognize.
<i>KSR</i> explicitly rejected the rigid application of the
teaching-suggestion-motivation test, explaining that "the
analysis need not seek out precise teachings directed to the
specific subject matter of the challenged claim, for a court
can take account of the inferences and creative steps that a
person of ordinary skill in the art would employ."
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 418</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>. The majority fails to follow
<i>KSR's</i> mandate in deciding that LTC's obviousness
defense lacked substantial merit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under the flexible approach of <i>KSR</i>, there is a
substantial question of obviousness concerning the &prime;<cite>929</cite>
patent. The patent spells out clearly &mdash; as does Celsis'
brief &mdash; that there was a need in the art to
multi-cryopreserve hepatocytes. The basic approach to determine
whether hepatocytes could be frozen multiple times and remain
viable was simply to pursue it. Celsis did and found that the
hepatocytes were viable. This process is not entitled to be
deemed an invention. <i>See KSR</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 421</a>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a> ("When there is a design need or market pressure to
solve a problem and there are a finite number of identified,
predictable solutions, a person of ordinary skill in the art
has good reason to pursue the known options within his or her
technical grasp," the invention is likely obvious.); <i>see</i>
<i>also Wyers v. Master Lock Co.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1DMPC6003?jcsearch=616%20f%203d%201231&amp;summary=yes#jcite">616 F.3d 1231</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1DMPC6003?jcsearch=616%20f%203d%201231&amp;summary=yes#jcite">1239</a>
(Fed. Cir. 2010) ("<i>KSR</i> and our later cases establish
that the legal determination of obviousness may include
recourse to logic, judgment, and common sense, in lieu of
expert testimony." (citations omitted)). I would thus vacate
the district court's grant of a preliminary injunction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>II.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court also erred in failing to appreciate that to
avoid a preliminary injunction, LTC needed only to offer proof
that the &prime;<cite>929</cite> patent was vulnerable, as opposed to clear
and convincing evidence of its invalidity. As the patentee,
Celsis bears the burden of proving that "in light of the
presumptions and burdens that will inhere at trial on the
merits," the &prime;<cite>929</cite> patent will withstand LTC's challenges
to its validity. <i>See Amazon.com, Inc. v.</i>
<i>Barnesandnoble.com, Inc.</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X50EPD?jcsearch=239%20f%203d%201343&amp;summary=yes#jcite">239 F.3d 1343</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X50EPD?jcsearch=239%20f%203d%201343&amp;summary=yes#jcite">1350</a>
(Fed. Cir. 2001). Thus, if LTC raises a substantial question as
to the &prime;<cite>929</cite> patent's validity, the preliminary injunction
should not issue. <i></i><a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X50EPD?jcsearch=239%20F.3d%201343&amp;summary=yes#jcite">Id. at 1350-51</a>. <i>See also</i>
<i>Genentech, Inc. v. Novo Nordisk AJS</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X4K9GE?jcsearch=108%20f%203d%201361&amp;summary=yes#jcite">108 F.3d 1361</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X4K9GE?jcsearch=108%20f%203d%201361&amp;summary=yes#jcite">1364</a>
(Fed. Cir. 1997) ("[W]ith <span CLASS="page_no" data-cite="2012 bl 3552 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> regard to [the alleged infringer's]
validity defenses, the question on appeal is whether there is
substantial merit to [its] assertion that the . . . patent
claim [is invalid]."); <i>Kimberly-Clark Worldwide, Inc. v.</i>
<i>First Quality Baby Products, LLC</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1FHBLA003?jcsearch=431%20f%20appx%20884&amp;summary=yes#jcite">431 Fed.Appx. 884</a>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1FHBLA003?jcsearch=431%20f%20appx%20884&amp;summary=yes#jcite">886-87</a> (Fed. Cir. 2011) (Prost, J.) (nonprecedential opinion)
(stating the same and that "[v]ulnerability is the issue at the
preliminary injunction stage, while validity is the issue at
trial") (citations omitted).
<span CLASS="page_no" data-cite="664 f 3d 935" data-cite-type="PrimaryFederalReporter" data-cite-pageno="935" data-primary-citation="664 F.3d 922">[*935]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Importantly, it is unnecessary to prove a substantial question
of invalidity by clear and convincing evidence. Rather, the
party challenging the patent's validity must show that the
patent is vulnerable, which "requires less proof than the clear
and convincing showing necessary to establish invalidity
itself." <i>Amazon</i>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X50EPD?jcsearch=239%20f%203d%201343&amp;summary=yes#jcite">239 F.3d at 1359</a>. Here, the district
court found that because LTC had not shown that every element
of the claimed invention was present in the prior art, its
obviousness defense lacked substantial merit. But as explained
<i><cite>supra</cite></i>, this is not the standard for obviousness.
Moreover, requiring the defendant to prove obviousness
improperly shifts the burden to the defendant. Instead, the
district court must simply decide whether it is more likely
than not that the patent will be proven invalid at trial.
<i>See Titan Tire Corp. v. Case New Holland, Inc.</i>,
<a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1B5Q44003?jcsearch=566%20f%203d%201372&amp;summary=yes#jcite">566 F.3d 1372</a>, <a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1B5Q44003?jcsearch=566%20f%203d%201372&amp;summary=yes#jcite">1379-80</a> (Fed. Cir. 2009) ("The fact that, at trial on
the merits, the proof of invalidity will require clear and
convincing evidence is a consideration for the judge to take
into account in assessing the challenger's case at the
preliminary injunction stage; it is not an evidentiary burden
to be met preliminarily by the challenger.")
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority affirms the district court's erroneous analysis,
stating that "LTC will have an opportunity at the merits stage
to expand <span CLASS="page_no" data-cite="101 uspq 2d 1163" data-cite-type="ReporterOfDecisions" data-cite-pageno="1163" data-primary-citation="101 U.S.P.Q.2d 1153">[**1163]</span> upon the arguments it made at the preliminary
injunction stage." <i>Majority Op.</i> at 928. While the
present record may not present a clear and convincing case for
obviousness, it certainly raises a substantial question on that
issue, which the majority implicitly recognizes. By relying on
the patent and admissions from Celsis' expert, LTC demonstrated
that all of the claim elements were present in the prior
art. From there, based on the need for multi-cryopreserved
hepatocytes, Celsis repeats the well-known steps to obtain its
desired result.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In my judgment, the district court abused its discretion in
finding that Celsis had demonstrated a likelihood of success on
the merits because the claimed invention is nothing more than a
repetition of steps already known in the art. Moreover, the
majority perpetuates this error, and in so doing applies the
wrong standard for obviousness and rationalizes the issuance of
the preliminary injunction because it would prevent competition
with a patented process which may be proven to be invalid. For
these reasons, I dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The majority also claims that the failure of LTC's
experts to practice the claimed invention weighs against
obviousness. Of course, had LTC's experts actually practiced
the claimed invention, it would be anticipated, not obvious. By
failing to appreciate this distinction the majority continues
to compound the error.
</p></div>
<!--BBLS DD 1681641242627-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1GU4Q2003/history">Direct History (3)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1GU4Q2003/analysis">Case Analysis (15)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1GU4Q2003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
15
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Biotechnology</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/document/X1Q6LEAAIKO2">10-01547 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Copyright Law</div><div class='facetItemLabel'>Damages &amp; Remedies</div><div class='facetItemLabel'>Patent Law</div><div class='facetItemLabel'>Trademark Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/35c10b58c7ceea3c31799530ef1ba5ee/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "35c10b58c7ceea3c31799530ef1ba5ee";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYc7c8bf&previousPageId=&previousActivityInstanceId=ENTITY3b591f&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:27:15-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1GU4Q2003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY3b591f&previousPageId=&previousActivityInstanceId=ENTITY81ca02&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:27:07-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1GU4Q2003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1GU4Q2003";
$('#page_loader').show().spin();
JUDGE_IDS=["1910097","3027446","4063892"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
